1832 Asset Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.69M | Sell |
46,089
-2,286
| -5% | -$108K | ﹤0.01% | 516 |
|
|
2025
Q4 | $2.46M | Buy |
+48,375
| New | +$2.47M | ﹤0.01% | 506 |
|
|
2024
Q4 | – | Sell |
-450,186
| Closed | -$53.6M | – | 705 |
|
|
2024
Q3 | $53.6M | Sell |
450,186
-1,170,600
| -72% | -$156M | 0.04% | 205 |
|
|
2024
Q2 | $231M | Sell |
1,620,786
-752,243
| -32% | -$99.7M | 0.19% | 67 |
|
|
2024
Q1 | $305M | Buy |
2,373,029
+172,003
| +8% | +$20.5M | 0.18% | 50 |
|
|
2023
Q4 | $228M | Buy |
2,201,026
+269,158
| +14% | +$26.6M | 0.33% | 64 |
|
|
2023
Q3 | $176M | Sell |
1,931,868
-399,000
| -17% | -$35.1M | 0.25% | 72 |
|
|
2023
Q2 | $189M | Buy |
+2,330,868
| New | +$190M | 0.22% | 71 |
|
|
2022
Q4 | – | Sell |
-559,876
| Closed | -$27.9M | – | 948 |
|
|
2022
Q3 | $27.9M | Sell |
559,876
-682
| -0.1% | -$36.5K | 0.05% | 247 |
|
|
2022
Q2 | $31.2M | Buy |
560,558
+92
| +0% | +$5.11K | 0.05% | 230 |
|
|
2022
Q1 | $30.7M | Buy |
560,466
+18,460
| +3% | +$947K | 0.04% | 259 |
|
|
2021
Q4 | $30.5M | Sell |
542,006
-150,670
| -22% | -$8.16M | 0.05% | 216 |
|
|
2021
Q3 | $33.5M | Buy |
692,676
+692,268
| +169,674% | +$33.5M | 0.06% | 209 |
|
|
2021
Q2 | $17K | Buy |
408
+180
| +79% | +$6.98K | ﹤0.01% | 673 |
|
|
2021
Q1 | $8K | Hold |
228
| – | – | ﹤0.01% | 660 |
|
|
2020
Q4 | $8K | Hold |
228
| – | – | ﹤0.01% | 670 |
|
|
2020
Q3 | $8K | Sell |
228
-550
| -71% | -$18.3K | ﹤0.01% | 652 |
|
|
2020
Q2 | $25K | Buy |
778
+550
| +241% | +$17.6K | ﹤0.01% | 583 |
|
|
2020
Q1 | $7K | Hold |
228
| – | – | ﹤0.01% | 638 |
|
|
2019
Q4 | $7K | Sell |
228
-112
| -33% | -$3.1K | ﹤0.01% | 624 |
|
|
2019
Q3 | $9K | Buy |
340
+112
| +49% | +$2.83K | ﹤0.01% | 634 |
|
|
2019
Q2 | $6K | Sell |
228
-100
| -30% | -$2.47K | ﹤0.01% | 647 |
|
|
2019
Q1 | $9K | Hold |
328
| – | – | ﹤0.01% | 572 |
|
|
2018
Q4 | $8K | Hold |
328
| – | – | ﹤0.01% | 566 |
|
|
2018
Q3 | $8K | Hold |
328
| – | – | ﹤0.01% | 600 |
|
|
2018
Q2 | $8K | Buy |
+328
| New | +$7.79K | ﹤0.01% | 580 |
|
|
2016
Q4 | – | Sell |
-1,236
| Closed | -$26K | – | 767 |
|
|
2016
Q3 | $26K | Buy |
1,236
+488
| +65% | +$12.1K | ﹤0.01% | 562 |
|
|
2016
Q2 | $20K | Sell |
748
-524
| -41% | -$14.4K | ﹤0.01% | 576 |
|
|
2016
Q1 | $34K | Buy |
1,272
+230
| +22% | +$6.16K | ﹤0.01% | 501 |
|
|
2015
Q4 | $30K | Buy |
+1,042
| New | +$28.8K | ﹤0.01% | 527 |
|
|
2014
Q4 | – | Sell |
-97,190
| Closed | -$2.32M | – | 650 |
|
|
2014
Q3 | $2.32M | Sell |
97,190
-7,160
| -7% | -$165K | 0.01% | 404 |
|
|
2014
Q2 | $2.41M | Buy |
104,350
+17,550
| +20% | +$387K | 0.01% | 408 |
|
|
2014
Q1 | $1.96M | Buy |
86,800
+71,800
| +479% | +$1.53M | 0.01% | 419 |
|
|
2013
Q4 | $278K | Hold |
15,000
| – | – | ﹤0.01% | 415 |
|
|
2013
Q3 | $253K | Buy |
+15,000
| New | +$252K | ﹤0.01% | 367 |
|
Other funds holding NVO
DAM
F
1832 Asset Management's NVO Position: Q1 2026 in Review
1832 Asset Management reduced its Novo Nordisk (NVO) stake by 4.7% in Q1 2026, selling an estimated $108K and leaving 46,089 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #516.
1832 Asset Management first reported a position in NVO in Q3 2013 and has held it in 35 quarters since. The position peaked at $305M in Q1 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- 1832 Asset Management held 46,089 shares of Novo Nordisk worth $1.69M as of Q1 2026.
- 1832 Asset Management sold 2,286 Novo Nordisk shares in Q1 2026, an estimated $108K.
- Novo Nordisk made up ﹤0.01% of 1832 Asset Management's portfolio in Q1 2026, its #516 holding.
- 1832 Asset Management first reported a position in Novo Nordisk in Q3 2013 and has held it in 35 quarters since.
- 1832 Asset Management's Novo Nordisk position peaked at $305M in Q1 2024.
- 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.